Gencurix Corrects Board Opinion Form in Merger Disclosure - No Change to Key Terms or Dilution

This amendment is an administrative correction to the board opinion form within the major disclosure on merger decision originally filed on June 25, 2026.
Key merger terms including the exchange ratio of 1 to 5.3591461 and the issuance of 742,456 new shares resulting in a 3.17% dilution remain unchanged.
The small-scale merger with Genofix proceeds without appraisal rights, though conversion to a regular merger is possible if opposing shareholders exceed 20%.
[AI Summary]This correction is a purely administrative form change with no impact on merger terms or financial outcomes. Minority shareholders retain limited exit options, and the original timeline and conditions remain in effect with no additional market shock.